The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 26, 2016

Filed:

Aug. 22, 2011
Applicants:

Itai Benhar, Rehovot, IL;

Assaf Shapira, Petach Tikva, IL;

Meital Gal-tanamy, Rehovot, IL;

Dana Greenfeld, Haifa, IL;

Limor Nahary, Givataim, IL;

Romy Zemel, Tel Aviv, IL;

Ran Tur-kaspa, Mevaseret Zion, IL;

Inventors:

Itai Benhar, Rehovot, IL;

Assaf Shapira, Petach Tikva, IL;

Meital Gal-Tanamy, Rehovot, IL;

Dana Greenfeld, Haifa, IL;

Limor Nahary, Givataim, IL;

Romy Zemel, Tel Aviv, IL;

Ran Tur-Kaspa, Mevaseret Zion, IL;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/29 (2006.01); A61K 39/385 (2006.01); C07K 16/46 (2006.01); C07K 14/21 (2006.01); C07K 14/415 (2006.01); C12N 9/14 (2006.01); C12N 9/50 (2006.01); C12N 15/62 (2006.01); C07K 14/195 (2006.01); C07K 14/32 (2006.01); C07K 14/37 (2006.01); C07K 14/705 (2006.01); C07K 16/10 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/46 (2013.01); C07K 14/195 (2013.01); C07K 14/21 (2013.01); C07K 14/32 (2013.01); C07K 14/37 (2013.01); C07K 14/415 (2013.01); C07K 14/705 (2013.01); C07K 16/1045 (2013.01); C07K 16/18 (2013.01); C12N 9/14 (2013.01); C12N 9/506 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.


Find Patent Forward Citations

Loading…